https://www.selleckchem.com/products/unc8153.html
Lifestyle modification is additive to lipid-lowering medications in the treatment of heterozygous familial hypercholesterolemia (HeFH), which does not respond sufficiently to statin therapy. While both are also important in homozygous familial hypercholesterolemia (HoFH), additional measures such as apheresis may be needed. The purpose of this review is to identify non-statin medications to lower cholesterol that are available for children and adolescents as adjunctive therapy. Ezetimibe is commonly used as second-line pharmacotherapy f
Gefällt mir
Kommentar
Teilen
